These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 18410441

  • 1. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
    Ellinger J, Müller SC, Wernert N, von Ruecker A, Bastian PJ.
    BJU Int; 2008 Aug 05; 102(5):628-32. PubMed ID: 18410441
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2000 Apr 05; 163(4):1183-8. PubMed ID: 10737491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):448-53. PubMed ID: 15890586
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [Abstract] [Full Text] [Related]

  • 11. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    Antunes AA, Srougi M, Dall'Oglio MF, Crippa A, Campagnari JC, Leite KR.
    BJU Int; 2005 Dec 01; 96(9):1258-63. PubMed ID: 16287441
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML.
    BJU Int; 2008 Feb 01; 101(3):299-304. PubMed ID: 17922854
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D.
    Clin Cancer Res; 2006 Aug 15; 12(16):4872-5. PubMed ID: 16914574
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM, Koch MO, Eble JN, Lin H, Cheng L.
    J Urol; 2006 May 15; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [Abstract] [Full Text] [Related]

  • 20. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL.
    J Natl Cancer Inst; 2006 Oct 04; 98(19):1420-4. PubMed ID: 17018789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.